You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2018

Practical Law Life Sciences Global Guide: Pharmaceutical IP and Competition Law in Thailand

Subscribe to Updates
Practical Law

The 2018 edition of Thomson Reuters’ Practical Law Life Sciences Global Guide  has been released, with a chapter on Pharmaceutical Intellectual Property and Competition Law in Thailand penned by legal practitioners from Tilleke & Gibbins.

The guide is a Q&A-style overview of the regulatory frameworks of the life sciences industries across multiple jurisdictions worldwide, with this chapter addressing the following issues as they relate to Thailand:

  • Pharmaceutical patent legislation and scope of protection
  • Patent application process, duration of protection, and revocation
  • Patent infringement, claims, and remedies
  • Non-patent barriers to competition for pharmaceutical protection
  • Pharmaceutical trademark legislation and scope of protection
  • Trademark application process, duration of protection, and revocation
  • Trademark infringement, claims, and remedies
  • Regulatory powers and enforcement against pharmaceutical counterfeiting
  • Competition law framework and implications for the pharmaceutical sector
  • Competition issues related to licensing of pharmaceutical technology and patents, and market entry of generic products
  • Market dominance issues in the pharmaceutical sector
  • Parallel imports
  • Foreign patent and trademark licenses, and payment of royalties

Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. Tilleke & Gibbins also drafted a chapter on Medicinal Product Regulation and Product Liability in Thailand for the 2018 edition of the guide.

Download Full Article
Related Professionals

Industries

Life Sciences

Practices

Antitrust and Competition

Customs and International Trade

Intellectual Property

Regulatory Affairs

Location

RELATED INSIGHTS​ 

July 20, 2018
Practical Law has published the 2018 edition of its Distribution and Marketing of Drugs Global Guide, a easily accessible Q&A overview of the key legal issues involved in bringing drugs to market in 29 jurisdictions worldwide. Members of the Tilleke & Gibbins life sciences team wrote the Vietnam chapter of this year’s guide.
Read More
July 20, 2018
Tilleke & Gibbins has contributed to the 2018 edition of the Distribution and Marketing of Drugs Global Guide, a Practical Law Company publication covering issues related to the distribution and marketing of drugs across 28 different jurisdictions.Providing their expertise in the guide’s Thailand chapter were Alan Adcock, partner and deputy director, Siraprapha Rungpry, consultant, and Dr. Atthachai Homhuan, regulatory affairs manager, from the Tilleke & Gibbins’ intellectual property group in Thailand. The chapter covers the following topics:
Read More
June 28, 2018
On June 19, 2018, Vietnam’s prime minister issued Directive No. 17/CT-TTg on strengthening the fight against smuggling, commercial fraud, and the production and trade of fake goods and low-quality goods for pharmaceuticals, cosmetics, and functional foods (Directive 17). Directive 17 states that, while tens of thousands of cases have been discovered and handled, the situation still needs improvement, as infringers are using more complex methods and are located not only in urban areas, but also in many remote regions.
Read More
May 25, 2018
The Medical Facility Act B.E. 2541 (1998) (also known as the Sanatorium Act) was recently amended by the Medical Facility Act (No. 4) B.E. 2559 (2016) which introduced a number of changes to Thailand’s regulation of private medical facilities, e.g. private clinics and hospitals, including those performing plastic surgery. Some of the most notable changes lie in the amended Section 38, which concerns advertisements. Previously, an advertisement for a medical facility was regulated post-publication and did not require any prior approval.
Read More